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Abstract
Background: Preterm delivery is one of the main causes of infant death. Therefore,
prediction of preterm delivery may eliminate a large number of prenatal complications.
Objective: The present study aimed to understand if preterm delivery can be predicted
by assessing maternal plasma fibronectin concentration.
Materials andMethods: Serum samples from 105 pregnant women participating in this
study were collected. The plasma fibronectin were measured at 24-28 wk of gestation
and again at 32-36 wk of gestation. Unfortunately, only 65 of the 105 pregnant women,
returned for the second sampling. The plasma fibronectin was analyzed using ELISA
method and its concentration in term and preterm deliveries was compared. The
delivery dates of all the women were also recorded.
Results: Out of 105 pregnant women, 28 delivered preterm (26.7%). The Plasma
fibronectin concentrations in women with preterm delivery were higher than in those
who delivered at term (p = 0.001). Accordingly, Plasma fibronectin concentrations
were significantly higher in the second serum samples (p = 0.01). Plasma fibronectin
concentrations was also higher in obese women and in those suffering from
preeclampsia (p = 0.12) and gestational diabetes (p = 0.81).
Conclusion: Plasma fibronectin concentrations test could be used as an optional
screening test for preterm delivery at 28 to 34 wk of gestation in pregnant women
who prefer to avoid vaginal sampling.
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1. Introduction
Preterm delivery is defined as delivery before
37 wk of gestation or 259 days after the last
menstrual period (LMP) (1, 2). It is one of the
main reasons for infant mortality in the world,
accounting for 35% of infant deaths annually (3,
4). Preterm delivery is still responsible for 70%
of neurological complications, disabilities, and
deaths, which impose a substantial economic
healthcare burden (5, 6). Several methods are
available for diagnosing, including investigation
of cervical dilation, assessment of cervical activity
with a dynamometer, performing sonography to
determine gestational age, evaluation of cervical
length using abdominal or vaginal ultrasound,
and evaluation of vaginal fibronectin levels
and salivary estriol (2). However, identification
by a reliable screening marker can predict
preterm delivery before the incidence of clinical
symptoms. Vaginal fibronectin concentration is
a reliable marker in the prognosis of preterm
delivery. However, its effectiveness may be
limited because of anxiety and cultural misgivings
among pregnant women about the method
of sampling, fibronectin secretion increases
due to endothelial stress (7-10). Thus, in the
case of preterm delivery, preeclampsia, and
intrauterine growth restriction (IUGR), fibronectin
concentration increases weeks and even months
before delivery. It is rarely found in discharges
after the 21st wk of gestation. However, it
increases again before delivery. Thus, the early
presence of fibronectin in cervical and vaginal
discharges can predict preterm delivery (11,
12).
For fetal fibronectin test, most samples are
taken through the vaginal route when the process
of preterm delivery begins. Because fibronectin
concentration increases earlier in maternal plasma
compared with vaginal discharges, Zygmunt
proposed that high Plasma fibronectin levels
could be effective in the prognosis of preterm
delivery. Plasma fibronectin concentration follows
an ascending trend in high-risk pregnancies (13).
Assessment of Plasma fibronectin concentration
is a simple, non-invasive, and accurate method
for investigation of endothelial function (11). In
Iran, pregnant women are reluctant to undergo
vaginal examination during pregnancy, believing
it is hazardous to infant health and may itself
cause preterm delivery. The availability of another
sampling option may help the patient as well as
the physician to evaluate the chance of preterm
delivery. Because blood sampling is simpler and
less invasive than vaginal sampling, the purpose
of the present study is to evaluate and compare
Plasma fibronectin concentrations in women that
delivered preterm and at term?”
2. Materials and Methods
This cross-sectional, descriptive-analytical study
was conducted in 105 pregnant women after
considering the inclusion and exclusion criteria.
The pregnant women had been referred to the
gynecology clinic in Vali-e-Asr Hospital, Fasa, Iran
for routine prenatal care between March 2014 and
April 2016.
The inclusion criteria included age (18-35
years old), single pregnancy, gestational age
of 24-28 and 32-36 wk; the exclusion criteria
included a history of receiving tocolytic agents
(terbutaline, ritodrine, magnesium sulfate,
salbutamol, and isoxsuprine) and suffering from
chronic hypertension, diabetes, renal problems,
and inflammatory disorders such as lupus. The
gestational age was determined according to
LMP. In case of doubt about the date of LMP,
the first-trimester sonography was taken into
consideration. Demographic data (parents’ ages,
occupations, and education levels) and obstetric
information were collected for each participant.
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A venous blood sample was collected, serum
separated, and kept at 𝜇70°C. All the samples were
assessed for fibronectin concentrations using 96-
well enzyme-linked immunosorbent assay (ELISA)
kits. The first sampling was undertaken at 24-28
wk of gestation and second sampling at 32-36
wk of gestation. However, samples could only
be taken from 65 women during the second
sampling period. All participants were followed
until delivery and information about infants’ weight,
type of delivery, and gestational age at the time
of delivery was collected and recorded. Plasma
fibronectin concentrations were assessed using
ELISA kits (BE59341 IBL international GMBH).
2.1. Ethical considerations
Women were informed about the study and
those who were interested to join, provided written
informed consents. This article was extracted from
a research proposal (93104) approved by Fasa
University of Medical Sciences.
2.2. Statistical analysis
All data were analyzed using SPSS statistical
software (IBM Corp. Released 2013. IBM SPSS
Statistics for Windows, Version 22.0. Armonk, NY:
IBM Corp.”). Descriptive statistics such as mean,
standard deviation (SD), and percentage were
used. The chi-square independent and paired
t-tests and a logistic regression analysis were
also employed. In addition, the receiver operating
characteristic (ROC) curve was used to assess the
cutoff points. The significance level was set at 𝛼 <
0.05.
3. Results
The results showed no significant differences
between the women with term and preterm
deliveries with respect to the mother’s age, father’s
age, and the interval between marriage and first
pregnancy (p = 0.51). There were also no significant
differences between the women with term and
preterm deliveries with respect to occupation,
education level, consanguineous (family) marriage,
parity, history of miscarriage, husband’s cigarette
smoking status, family history of preterm delivery,
contraception method, and utilization of assisted
reproductive techniques (ART) (p = 0.49). However,
the body mass index (BMI) before pregnancy was
higher among women in the preterm delivery
group (p = 0.01), which continued throughout
pregnancy. Higher fibronectin concentration was
accompanied by lower infant weight (p = 0.001)
(Table I).
The results revealed that 28 participants had
preterm delivery (26.7%). Among the women with
preterm delivery, 13 had natural vaginal delivery
(NVD) (46.4%) and 15 had a cesarean section(C/S)
(53.6%). These measures (NVD or C/S) were 57.1%
and 42.9%, respectively, in the term delivery group
(p = 0.33). According to the results, two women
in the preterm delivery group (7.1%) and three
women in the term delivery group (3.9%) had
unplanned pregnancies (p = 0.009). Besides, 53.6%
of the women in the preterm delivery group and
31.2% of those in the term delivery group had
a family history of diabetes and hypertension (p
= 0.03). Additionally, 17.9% of the women in the
preterm delivery group and 10.4% of those in the
term delivery group reported a history of preterm
delivery in their mothers or sisters. However, the
difference was not statistically significant (p = 0.30)
(Table I). Out of 65 women who took part in the
second sampling, 11 had preterm delivery and 54
had term delivery. At the first sampling (24−28
wk), the results of fibronectin concentrations
revealed no significant difference (p = 0.66). Plasma
fibronectin concentrations in the term delivery
group decreased in the second sampling, but
the difference was not statistically significant (p
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= 0.16). However, in contrast, the mean plasma
fibronectin concentration significantly increased
in the preterm delivery group (p = 0.01). In
other words, the increase in gestational age was
accompanied by a significant increase in the
fibronectin concentration in the preterm delivery
group (p = 0.001) (Table II and III). With respect
to pregnancy complications, the incidence of
diabetes and hypertension was higher in women
in the preterm delivery group. Moreover, plasma
fibronectin concentrations were significantly higher
in the women suffering from gestational diabetes
and preeclampsia (p = 0.009) (Tables IV and
V).
According to the ROC curve, the best cutoff
point in the first sampling was 1.750 ng/ml with a
sensitivity of 80.26%, specificity of 17.85%, positive
predictive value of 73/08%, and negative predictive
value of 26/92%. In the second sampling, the best
cutoff point was 4,226 ng/ml with a sensitivity of
100%, specificity of 74%, positive predictive value of
76/67%, and negative predictive value of 23/33%.
According to these measures, this test should be
used after the 28th wk of gestation (Figures 1, 2).
Table I. Frequency distribution and comparison of demographic, labor, and individual factors in two groups
Personal and delivery details, and maternal factors Preterm N = 28
(26.7%)
Term N = 77
(73.3%)
Total N = 150
(100%)
P-value
Mother’s age (yr) * 29.47 ± 5.56 28.57 ± 6.50 28.81 ± 6.257 0.51∗
Husband’s age (yr)* 35.39 ± 7.28 33.45 ± 6.03 33.97 ± 6.417 0.17
The average age of marriage for women (yr) * 22.21 ± 5.39 21.70 ± 4.66 21.84 ± 4.84 0.63
Time span between the age of marriage and the first
pregnancy (yr) *
2.25 ± 1.79 2.57 ± 3.20 2.49 ± 2.84 0.63
Gestational age in the first sampling (wk) * 26.45 ± 2.68 26.16 ± 2.33 26.1 ± 2.98 0.87
Gestational age in the second sampling (wk) * 31.18 ± 3.10 32.33 ± 2.74 30.90 ± 2.35 0.42
Gestational age at birth (wk) * 35.12 ± 1.10 39.25 ± 2.13 38.24 ± 2.03 0.012
Mother’s weight at first sampling (kg) * 65.3 ± 10.56 60.42 ± 10.74 61.72 ± 10.867 0.42
Maternal weight at delivery (Kg) * 74.25 ± 12.33 67.54 ± 12.24 69.33 ± 12.566 0.17
Maternal BMI before pregnancy * 26.24 ± 346 24.18 ± 3.88 24.73 ± 3.87 0.01
Delivery type **
NVD 13 (46.4) 44 (57.1)
C/S 15 (53.6) 37 (42.9)
0.33∗∗
Mother’s job **
Housewife 22 (78.6) 71 (92.2)
Employed 6 (21.4) 6 (7.8)
0.15
Husband’s job**
The manual worker 2 (7.1) 16 (20.8)
Employee 8 (28.6) 16 (20.8)
Freelancer 18 (64.3) 45 (58.4)
0.34
Mother’s education **
Illiterate 2 (7.1) 1 (1.3)
Under the diploma 7 (15) 27 (35.1)
Academic 19 (67.8) 49 (63.7)
0.37
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Table I. Continued.
Personal and delivery details, and maternal factors Preterm N = 28
(26.7%)
Term N = 77
(73.3%)




Illiterate 1 (3.6) 5 (6.5)
Under the diploma 15 (53.6) 53 (68.8)
Academic 12 (42.8) 19 (24.7)
0.08
Gravid **
1 13 (6.4) 27 (35.1)
2 8 (28.6) 27 (35.1)
3≥ 7 (25) 23 (29.8)
0.70
Abortion history **
Yes 4 (14.3) 19 (24.7)
No 24 (85.7) 58 (75.3)
0.25
Smoking by husband **
Yes 6 (21.4) 14 (18.2)
No 22 (78.6) 63 (81.8)
0.70
Preterm labor history **
Yes 23 (82.1) 69 (89.6)
No 5 (17.9) 8 (10.4)
0.30
Use of fertility assisted methods **
Yes 2 (7.1) 3 (3.9)
No 26 (92.9) 74 (96.1)
0.49
Disease in the current pregnancy **
GDM 4 (14.28) 1 (1.31)
PEC 4 (14.28) 2 (2.63)
Infection 7 (25) 19 (25)
Vaginal bleeding 1 (3.57) 10 (13.15)
0.009
* Mean ± SD, **n (%), P-value∗, Qualitative variables were analyzed using an independent t-test, P-value∗∗, Chi-square test
NVD: Normal vaginal delivery, C/S: Cesarean section, GDM: Gestational diabetic mellitus, PEC: Preeclampsia
Table II. Comparison of mean plasma concentrations of fibronectin in two groups in double sampling
Variable Fibronectin plasma1 Fibronectin plasma2 P-value∗
Term 7727.50 ± 11506.734 4059.57 ± 3175.744 0.16
Preterm 6726.43 ± 7174.916 10507.14 ± 5477.106 0.01
P-value∗∗ 0.668 0.001
* Mean ± SD, Qualitative variables were analyzed using an independent and dependent t-test and quantitative variables were
analyzed using logistic regression test, P-value∗, paired sample t-test; P-value∗∗, independent t-test
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Table III. Comparison of mean of fibronectin concentrations in the first and second sampling groups
Variable N Mean ± SD p-value
Fibronectin plasma1 30 4366.66 ± 5209.09
Fibronectin plasma2 30 5564 ± 4642.26
0.009
* Mean ± SD, P-value, paired sample t-test
Table IV. Comparison of fibronectin concentration in women with gestational diabetes and non-diabetes individuals
Fibronectin GDM Fibronectin plasma 1 Fibronectin plasma 2
Mean ± SD N Mean ± SD N
Yes 6508.75 ± 5175.02 8 6166.67 ± 3663.78 3
No 7537.08 ± 10831.50 96 5497.04 ± 4791.46 27
P-value 0.791 0.817
* Mean ± SD, P-value: Independent t-test, GDM: Gestational diabetic mellitus
Table V. Comparison of fibronectin concentration in women with preeclampsia and non-affected patients
Fibronectin Preeclampsia Fibronectin plasma 1 Fibronectin plasma 2
Mean ± SD N Mean ± SD N
Yes 9581.67 ± 7356.95 6 12600 1
No 7327.96 ± 10669.99 96 5321.38 ± 4526.73 29
P-value 0.612 0.125
* Mean ± SD, P-value: Independent t-test
Figure 1. Receiver operating characteristic curve for fibronectin plasma 1.
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Figure 2. Receiver operating characteristic curve for fibronectin plasma 2.
4. Discussion
The results indicated that plasma fibronectin
concentration was higher in the women who
had given birth to their children before 37 wk of
gestation, which is consistent with the study by
Zigmunt (13). Forouhari and colleagues compared
maternal plasma fibronectin concentration in
three study groups, including women with
symptoms and risk factors of preterm delivery,
women with symptoms but without risk factors of
preterm delivery, and healthy pregnant women.
The results showed that plasma fibronectin
concentration was significantly higher in the
preterm delivery group compared with the term
delivery group (2). Severens-Rijvers also evaluated
fibronectin concentration before pregnancy and
at 12 and 16 wk of gestation. Based on the
results, fibronectin concentration was higher in
women with maternal placental syndrome and had
increased since before pregnancy up to the 16th
wk of gestation. However, in women without the
maternal placental syndrome, this value increased
up to the 12th wk of gestation but decreased below
the pre-pregnancy value at wk 16th (11). The results
of our study are consistent with the findings of
the above studies. Thus, it can be concluded
that plasma fibronectin concentration follows
an ascending trend in high-risk pregnancies.
It usually increases weeks and even months
before the incidence of complications, such
as preterm delivery, preeclampsia, and IUGR
(13). Increased plasma fibronectin concentration
may result from its secretion from damaged
endothelial cells occurring in placentas of women
experiencing preterm delivery (13). In this regard,
vascular problems and inflammatory markers
affect plasma fibronectin concentration. These
changes are similar to those occurring in IUGR
and preeclampsia (14). In the present study,
only 65 out of the 105 participants took part
in the second sampling. Among these women,
58 and 7 belonged to the term and preterm
delivery groups, respectively. Comparing the
results of fibronectin concentration in the first
and second sampling for those who attended
for the second time showed that an increase in
gestational agewas accompanied by an increase in
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fibronectin concentration, which is consistent with
studies by Ekaidem and Dane (14, 15). Production
and secretion of fibronectin into body fluids is
accompanied by the natural growth of placental
and trophoblastic villi, which increase with an
increase in gestational age (14). The results of the
present study revealed that an increase in BMI
before pregnancy and an increase in the mother’s
weight at the time of delivery led to an increase in
plasma fibronectin concentration. In contrast, an
early increase in plasma fibronectin concentration
leads to preterm delivery. Moreover, five women
developed gestational diabetes and six developed
preeclampsia. Of these, eight in total underwent
preterm delivery. Fibronectin concentration was
also higher in womenwith gestational diabetes and
hypertension. These results were similar to those
obtained by Ekaidem and Rasanen, which showed
that plasma fibronectin concentration and the risk
of preeclampsia were higher among obese women
(14, 16). The relationship between increased plasma
fibronectin concentration and risk of preeclampsia
in obese women may be attributed to obesity
complications. Hypertension in obese individuals
can reduce placental perfusion and increase
vascular problems, which eventually increase the
production and secretion of fibronectin as well as
the production of pro- inflammatory products
(14, 16). Parker and Kim also demonstrated
that maternal obesity was accompanied by
increased risk of preterm delivery due to medical
complications such as gestational diabetes and
blood pressure disorders. Thus, interventional
strategies for reducing the risk of gestational
diabetes and blood pressure disorders could
decrease the risk of preterm delivery as well
(17, 18). Thus, evaluation of mothers’ weight and
BMI before pregnancy and at the first visit after
that, nutritional consultation, and provision of
necessary care services could play an important
role in maternal and infantile health and prevention
of undesirable complications. Health behaviors
and lifestyle modifications, as well as weight
adjustment, are essential during pregnancy
in order to have a healthy delivery and avoid
complications and negative outcomes (19-22). The
results of the present study showed that plasma
fibronectin concentration decreased in the second
sampling compared with the first sampling in the
term delivery group. Considering the fact that
the increase in plasma fibronectin concentration
is indicative of preterm delivery, this finding
followed the normal trend of changes in fibronectin
concentration during pregnancy (10). However, this
measure was significantly higher in the second
sampling compared with the first sampling in the
preterm delivery group. This implies that factors
leading to preterm delivery follow an ascending
trend and that plasma fibronectin concentration
increases over time.
In the studies by Zigmunt and Forouhari
(2, 13), plasma fibronectin concentration was
assessed in women who showed symptoms of
preterm delivery. However, the present study
aimed to determine whether plasma fibronectin
concentration could be used as a screening test.
Therefore, the participants were selected from
women who had no symptoms of preterm delivery.
In addition, blood was taken at two stages with a 4-
6 wk interval in order to determine the best time for
performing the test. Zigmunt et al. also reported
the highest plasma fibronectin concentration
(600 ± 160) in the women who had given birth
to their children before 32 wk of gestation
(21). In Forouhari’s study, plasma fibronectin
concentration was higher in the preterm delivery
group compared with the term delivery group,
with the best cutoff point being 700 ng/ml. The
difference between the results may be because
of the kits utilized. Moreover, Forouhari reported
sensitivity, specificity, positive predictive value,
and negative predictive value to be 100%, 61.1%,
54.3%, and 100%, respectively. The present study
benefitted from higher specificity (2). However,
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Zigmunt et al. measured fibronectin concentration
using the nephelometry method and reported the
cutoff point to be 450 ng/ml. Indeed, sensitivity,
specificity, positive predictive value, and negative
predictive value were reported to be 50%, 95%,
50%, and 90%, respectively (13). As mentioned
above, Zigmunt assessed fibronectin concentration
using the nephelometry method, while ELISA is a
more accurate technique. In the present study, the
prevalence of preterm delivery was 26.7%. Various
prevalence rates have been reported in different
studies. For instance, Forouhari et al. reported
the prevalence of preterm delivery to be 31.6% in
Shiraz (2). Additionally, Shojae and Shariati showed
that the prevalence of the condition was 7.2% in
Bojnourd and 15.4% in Tehran and around the
world (6, 23). These differences may be attributed
to various causes of preterm delivery in different
cultural and geographical regions. The findings of
the present study demonstrated that an increase
in plasma fibronectin concentration resulted in a
decrease in birth weight. This decrease may have
resulted because of preterm delivery. Similarly,
Forouhari and Zigmunt found that an increase
in plasma fibronectin concentration caused a
decrease in birth weight (2, 13). Given that only two
studies have been conducted on the assessment
of plasma fibronectin concentration for predicting
preterm delivery, limited studies were available
for comparison of the results. Moreover, sampling
was not undertaken in several stages in the
previous studies to evaluate changes in fibronectin
concentration in preterm delivery. Thus, further
studies may help to achieve more reliable results
regarding this issue.
5. Conclusion
Plasma fibronectin concentration can predict the
process of preterm delivery earlier than the fetal
fibronectin test. Therefore, it can be used as a
screening test in the prognosis of preterm delivery.
We suggest the best time for analysis to be after
30 wk of pregnancy. We have undertaken another
study to evaluate and compare fetal and plasma
fibronectin concentrations at the same time in the
same patients.
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